<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-158
Date of Submission: 2025-07-09

This report was submitted by a Other Healthcare Professional from Ward, Flores and Hernandez Medical Center concerning patient ANON-PX-8681. The subject is a 22-year-old other with a significant medical history including chronic kidney disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 363mg, initiated on 2025-05-04 for Neuropathic pain with the course ongoing; Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 162mg, initiated on 2025-05-04 for Thromboembolism prevention with the course ongoing.

On approximately 2025-05-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Stevens-Johnson syndrome. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed father and advised happen. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Well ahead rather look face already lose. Someone discuss bar know future amount.</data>
report_id: ADR-2025-158
report_date: '2025-07-09'
patient_details:
  patient_id: ANON-PX-8681
  gender: Other
  relevant_history:
  - chronic kidney disease
  - atrial fibrillation
  age_at_reaction: 22
suspected_drugs:
- drug_name: Gabapentin
  dosage: 363mg
  route_of_administration: Topical
  start_date: '2025-05-04'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
- drug_name: Warfarin
  dosage: 162mg
  route_of_administration: Intravenous
  start_date: '2025-05-04'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Angioedema
  onset_date: '2025-05-12'
  severity: Severe
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-05-12'
  severity: Severe
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed father and advised happen.
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 10
reporting_facility: Ward, Flores and Hernandez Medical Center
reporter_type: Other Healthcare Professional
notes: Well ahead rather look face already lose. Someone discuss bar know future amount.
